Skip to main navigation Skip to search Skip to main content

A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult and adolescent participants with moderate to severe hidradenitis suppurativa.

  • Kern, Johannes (Primary Chief Investigator (PCI))
  • Fernandez-Penas, Pablo (Chief Investigator (CI))
  • Nicolopoulos, Jenny (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date27/04/26 → 29/04/30

Keywords

  • clinical trials
  • Phase 3 extension
  • hidradenitis suppurativa

Clinical Trial Phase

  • Phase III (a & b)
  • External Sponsor